Clinical trial · Observational
Natural Disease Progress of Dupuytren Disease
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Dupuytren disease (DD) is a progressive fibromatosis of the palmar fascias of the hand and fingers, which may lead to extension deficits of the fingers. The disease can be very disabling in moderate and severe cases, whereby performing normal daily activities can become very problematic. The aetiology and pathogenesis are not completely understood. There is a genetic disposition and it is influenced by environmental factors. The disease is especially prevalent in white males of Northern European descent above 50 years of age. There is paucity of knowledge about the natural progression of the disease. Several studies have been conducted on progression of disease and from these studies it becomes obvious that the disease is progressive over several years. However, in most studies only one moment of follow-up has taken place, so the course of the progression over time is unknown. The aim of this study is to enhance our knowledge on the natural disease progression of DD at different stages.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Disease Progression | — | UNRESOLVED | — |
| Dupuytren Contracture | Palmar Fibromatosis | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- The course of DD: passive and active extension deficit and dimension of palpable nodules and cords
- timeFrame
- every 6-12 months
- description
- Active and passive extension deficit is measured with a goniometer at joint level Dimension of nodules and cords is measured using a tumorimeter
Secondary outcomes (2)
- measure
- Disease activity: Echogenicity and nodule hardness
- timeFrame
- every 12 months, starting from 2016 (ultrasound) and 2018 (tonometry)
- description
- Activity of a nodule is determined by 1) echogenicity of the ultrasound image in sagittal and transversal plane, 2) hardness of the nodule determined by tonometry
- measure
- Patient-reported hand function: MHQ, PRWHE and URAM
- timeFrame
- every 6-12 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients (\> 18 years of age) with primary Dupuytren's disease in all Tubiana stages * Operated hands of patients with primary Dupuytren's disease on the contra lateral hand Exclusion Criteria: * Patients who are incapable of giving consent * Patients who are not able or not willing to visit the UMCG for follow-up * Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
References
Publications (0)
Data not yet available